Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01272791 · ClinicalTrials.gov registry record · Phase 2
Trial of Gemcitabine With or Without Bavituximab in Patients With Previously Untreated Stage IV Pancreatic Cancer
A Phase 2 study, sponsored by Peregrine Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 70
- Enrollment target
NCT01272791 is a Phase 2 study that has completed, run by Peregrine Pharmaceuticals. The registered enrollment target is 70 participants.
The verdict
NCT01272791, a Phase 2 study, has completed, sponsored by Peregrine Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 70 participants
- Enrollment target
Study Summary
The primary objective of this study is to compare the overall survival of patients with stage IV pancreatic cancer treated with gemcitabine alone or gemcitabine with bavituximab.
Interventions
- DRUG Gemcitabine
- BIOLOGICAL bavituximab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2011-01 |
| Est. Completion | 2013-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01272791
The ClinicalTrials.gov registry entry for NCT01272791 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Peregrine Pharmaceuticals, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Gemcitabine is the first listed.
NCT01272791 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01272791 about?
NCT01272791 is a clinical study titled "Trial of Gemcitabine With or Without Bavituximab in Patients With Previously Untreated Stage IV Pancreatic Cancer". The primary objective of this study is to compare the overall survival of patients with stage IV pancreatic cancer treated with gemcitabine alone or gemcitabine with bavituximab.
What is the current status of trial NCT01272791?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 70 participants. The study started on 2011-01. Estimated completion is 2013-03.
What interventions are being tested in trial NCT01272791?
The interventions under investigation include: Gemcitabine (DRUG), bavituximab (BIOLOGICAL).
Who is sponsoring clinical trial NCT01272791?
This trial is sponsored by Peregrine Pharmaceuticals, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.